-
24 Oct 2026
Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
The New England Journal of Medicine
- Views 4
- More stats
-
24 Oct 2026
Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy
The New England Journal of Medicine
- Views 4
- More stats
-
24 Oct 2026
Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion
The New England Journal of Medicine
- Views 3
- More stats
-
24 Oct 2026
Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke
The New England Journal of Medicine
- Views 4
- More stats
-
24 Oct 2026
Anbenitamab plus HB1801 for HER2-Positive Advanced Breast Cancer
The New England Journal of Medicine
- Views 4
- More stats
-
24 Oct 2026
Expanding the Evidence and Indications for Thrombectomy in Ischemic Stroke
The New England Journal of Medicine
- Views 4
- More stats
-
24 Oct 2026
Targeting HER2 — A Triumph of Science
The New England Journal of Medicine
- Views 4
- More stats
-
24 Oct 2026
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial
Nature Medicine
- Views 4
- More stats
-
24 Oct 2026
[News] US EPA research and oversight on carcinogens are in disarray, critics contend
The Lancet Oncology
- Views 11
- More stats
-
24 Oct 2026
[News] Proposed Mexican reform would set 60-day limit for cancer treatment
The Lancet Oncology
- Views 13
- More stats
Journal Content
Life Science Network features journal content imported from some of the most popular scientific journals. In addition, the Publications module allows you to import or add your own publications to our database. Note that the indicated journal impact factors are not regularly updated.
Check the Publications module here
Advertisement